Title: Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
Abstract: 8021 Background: In ASPIRE, KRd achieved superior progression free survival (PFS) (HR = 0.69; p = 0.0001) and improved quality of life (QoL) (p < 0.001) over Rd in patients (pts) with R/RMM. We assessed the cost-effectiveness (CE) of KRd vs Rd from a US payer perspective with data from ASPIRE and long-term overall survival (OS) data from the Surveillance, Epidemiology, and End Results Program (SEER). Methods: A partitioned-survival model with progression-free (PF), post-progression (PP) and death states was built with a 30 year horizon. Treatment (Tx) effect for PFS and OS was estimated with parametric regression models and applied over the time horizon. Since 60% of pre-specified OS events were observed, post-trial OS transition probabilities were estimated by matching SEER data to ASPIRE pts. Grade ≥ 3 adverse events (AEs) with > 2% incidence in any ASPIRE arm were included. Utilities were derived from literature and adjusted for the relative improvement in QoL increase observed when pts were PF in ASPIRE. Costs related to drug (WAC prices) as well as wastage (30% for carfilzomib), administration, monitoring, AE management, and subsequent Tx were considered. Tx duration was derived fitting ASPIRE data and carfilzomib was dosed upto 18 cycles. The base case assessed the CE of adding carfilzomib to Rd, and considered only additional costs of carfilzomib, i.e. neglecting Rd drug costs in both arms. A scenario including Rd costs in both arms was conducted. A 3% discount rate was applied to costs and outcomes. Results: KRd was more effective compared to Rd, providing 1.134 PF life year, 1.927 life year, and 1.616 quality-adjusted life year (QALY) gains over the modelled horizon. KRd incurred $123,524 in total additional costs. Incremental CE ratio (ICER) was 76,416$/QALY. With the inclusion of Rd costs, KRd incurred $179,863 additional costs with an ICER of 111,270$/QALY. Conclusions: The model predicts that KRd delivers nearly 2 additional life year’s over the standard of care (Rd), and is cost-effective vs. Rd at a willingness-to-pay threshold of 120,000$/QALY. Therefore, carfilzomib when added to Rd delivers considerable incremental value to patients and payers.
Publication Year: 2016
Publication Date: 2016-05-20
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot